Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Global | Policy/Regulation | Health Systems | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Microsimulation | North America | Policy/Regulation | Health Systems | Environmental Health | Mathematical Models | State-Transition | Dynamic Simulation | Decision Analysis | Chronic Disease/Risk | Business/Industry | Climate/Environment | Government/Law | Health/Medicine -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | North America | Global | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine -
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Microsimulation | Benefit-Cost Analysis | Global | Health Systems | Priority Setting/Ethics | Health Outcomes | Chronic Disease/Risk -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Microsimulation | North America | Policy/Regulation | Health Systems | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Benefit-Cost Analysis | Global | Policy/Regulation | Environmental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Injuries/Accidents | Global Governance | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine -
Resource PackPublication, Teaching Resource 2018Resource Pack: Economic Evaluation Guidelines
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure …
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure and value the incremental resources used, relative to benefits gained, of alternative interventions or policies - with the goal of improving resource allocation decisions by addressing efficiency in healthcare. The selected examples focus predominantly on the conduct of cost-effectiveness analysis. Over the past three decades, cost-effectiveness analysis has gained increasing attention from decision makers in both resource-rich and resource-poor countries.…
Benefit-Cost Analysis | Global | Policy/Regulation | Health Systems | Preferences/Values | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Climate/Environment | Economics/Finance | Government/Law | Health/Medicine | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | North America | Policy/Regulation | Mental Health | Preferences/Values | Costing Methods | Chronic Disease/Risk | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | North America | Global | Health Systems | Test Performance | State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine